Literature DB >> 27271348

Of the multiple mechanisms leading to type 1 diabetes, T cell receptor revision may play a prominent role (is type 1 diabetes more than a single disease?).

D H Wagner1.   

Abstract

A single determinant factor for autoimmunity does not exist; disease development probably involves contributions from genetics, the environment and immune dysfunction. Type 1 diabetes is no exception. Genomewide-associated studies (GWAS) analysis in T1D has proved disappointing in revealing contributors to disease prediction; the only reliable marker has been human leucocyte antigen (HLA). Specific HLAs include DR3/DR4/DQ2/DQ8, for example. Because HLA molecules present antigen to T cells, it is reasonable that certain HLA molecules have a higher affinity to present self-antigen. Recent studies have shown that additional polymorphisms in HLA that are restricted to autoimmune conditions are further contributory. A caveat is that not all individuals with the appropriate 'pro-autoimmune' HLA develop an autoimmune disease. Another crucial component is autoaggressive T cells. Finding a biomarker to discriminate autoaggressive T cells has been elusive. However, a subset of CD4 helper cells that express the CD40 receptor have been described as becoming pathogenic. An interesting function of CD40 on T cells is to induce the recombination-activating gene (RAG)1/RAG2 T cell receptor recombination machinery. This observation is contrary to immunology paradigms that changes in TCR molecules cannot take place outside the thymic microenvironment. Alteration in TCR, called TCR revision, not only occurs, but may help to account for the development of autoaggressive T cells. Another interesting facet is that type 1 diabetes (T1D) may be more than a single disease; that is, multiple cellular components contribute uniquely, but result ultimately in the same clinical outcome, T1D. This review considers the process of T cell maturation and how that could favor auto-aggressive T cell development in T1D. The potential contribution of TCR revision to autoimmunity is also considered.
© 2016 British Society for Immunology.

Entities:  

Keywords:  TCR revision; autoimmune diabetes; immune dysfunction

Mesh:

Substances:

Year:  2016        PMID: 27271348      PMCID: PMC4991519          DOI: 10.1111/cei.12819

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  127 in total

Review 1.  Thymic selection revisited: how essential is it?

Authors:  Harald von Boehmer; Iannis Aifantis; Fotini Gounari; Orly Azogui; Loralee Haughn; Irina Apostolou; Elmar Jaeckel; Fabio Grassi; Ludger Klein
Journal:  Immunol Rev       Date:  2003-02       Impact factor: 12.988

Review 2.  Revision of the antigen receptor of T-lymphocytes.

Authors:  E M Kuklina
Journal:  Biochemistry (Mosc)       Date:  2006-08       Impact factor: 2.487

3.  CD40 on NOD CD4 T cells contributes to their activation and pathogenicity.

Authors:  Rocky L Baker; David H Wagner; Kathryn Haskins
Journal:  J Autoimmun       Date:  2008-10-31       Impact factor: 7.094

4.  Re-expression of RAG-1 and RAG-2 genes and evidence for secondary rearrangements in human germinal center B lymphocytes.

Authors:  C Giachino; E Padovan; A Lanzavecchia
Journal:  Eur J Immunol       Date:  1998-11       Impact factor: 5.532

5.  CD1-restricted microbial lipid antigen-specific recognition found in the CD8+ alpha beta T cell pool.

Authors:  J P Rosat; E P Grant; E M Beckman; C C Dascher; P A Sieling; D Frederique; R L Modlin; S A Porcelli; S T Furlong; M B Brenner
Journal:  J Immunol       Date:  1999-01-01       Impact factor: 5.422

6.  An immunocytochemical and morphometric study of the rat pancreatic islets.

Authors:  A A Elayat; M M el-Naggar; M Tahir
Journal:  J Anat       Date:  1995-06       Impact factor: 2.610

7.  Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity.

Authors:  Janet G M Markle; Daniel N Frank; Steven Mortin-Toth; Charles E Robertson; Leah M Feazel; Ulrike Rolle-Kampczyk; Martin von Bergen; Kathy D McCoy; Andrew J Macpherson; Jayne S Danska
Journal:  Science       Date:  2013-01-17       Impact factor: 47.728

8.  An alternative role for Foxp3 as an effector T cell regulator controlled through CD40.

Authors:  Gisela M Vaitaitis; Jessica R Carter; Dan M Waid; Michael H Olmstead; David H Wagner
Journal:  J Immunol       Date:  2013-06-17       Impact factor: 5.422

Review 9.  Mechanics of T cell receptor gene rearrangement.

Authors:  Michael S Krangel
Journal:  Curr Opin Immunol       Date:  2009-04-09       Impact factor: 7.486

10.  The effect of neonatal sex hormone manipulation on the incidence of diabetes in nonobese diabetic mice.

Authors:  T Hawkins; R R Gala; J C Dunbar
Journal:  Proc Soc Exp Biol Med       Date:  1993-02
View more
  5 in total

1.  CD40-mediated signalling influences trafficking, T-cell receptor expression, and T-cell pathogenesis, in the NOD model of type 1 diabetes.

Authors:  Gisela M Vaitaitis; Dan M Waid; Martin G Yussman; David H Wagner
Journal:  Immunology       Date:  2017-06-19       Impact factor: 7.397

2.  Biomarker discovery in pre-Type 1 Diabetes; Th40 cells as a predictive risk factor.

Authors:  Gisela M Vaitaitis; Marynette Rihanek; Aimon K Alkanani; Dan M Waid; Peter A Gottlieb; David H Wagner
Journal:  J Clin Endocrinol Metab       Date:  2019-05-07       Impact factor: 5.958

Review 3.  Overlooked Mechanisms in Type 1 Diabetes Etiology: How Unique Costimulatory Molecules Contribute to Diabetogenesis.

Authors:  David H Wagner
Journal:  Front Endocrinol (Lausanne)       Date:  2017-08-23       Impact factor: 5.555

Review 4.  Natural Killer Cells in the Orchestration of Chronic Inflammatory Diseases.

Authors:  Luca Parisi; Barbara Bassani; Marco Tremolati; Elisabetta Gini; Giampietro Farronato; Antonino Bruno
Journal:  J Immunol Res       Date:  2017-03-27       Impact factor: 4.818

Review 5.  Towards Clinical Translation of CD8+ Regulatory T Cells Restricted by Non-Classical Major Histocompatibility Complex Ib Molecules.

Authors:  Samiksha Wasnik; David J Baylink; Jianmei Leavenworth; Chenfan Liu; Hongzheng Bi; Xiaolei Tang
Journal:  Int J Mol Sci       Date:  2019-09-28       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.